Block Grant R43AI069666

Novobiotic Pharmaceuticals, LLC received a $4.5 million Project Grant award from the Defense Health Agency to conduct late-stage preclinical development of the antibiotic teixobactin through April 2026. The funding supports research under the Military Medical Research and Development program, which aims to develop medical solutions for battlefield injuries and infectious diseases. Specifically, the award will allow Novobiotic to advance teixobactin, initially discovered using its iChip...

Microbiotix, Inc. received a $1,023,646 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) to develop oxadiazole inhibitors targeting bacterial nonstop ribosome rescue mechanisms. The award, effective August 1, 2025 through July 31, 2027, supports research and development of novel pharmaceutical compounds designed to treat tick-borne diseases, specifically Lyme disease and tularemia in military personnel, veterans, and...

This National Science Foundation (NSF) Small Business Innovation Research (SBIR) Phase I award to Bactria Pharmaceuticals LLC is providing $274,937 to develop therapeutic drugs that restore antibiotic sensitivity in bacteria that cause severe healthcare-associated infections. The goal is to combat antimicrobial resistance in gram-negative pathogens through the use of small molecule efflux pump inhibitors (EPIs). The project involves three key activities: cryo-electron microscopy to understand...

The National Institutes of Health's National Institute of General Medical Sciences awarded Oragenics, Inc. a $769,962 Project Grant under the Biomedical Research and Research Training program (CFDA 93.859) to support computer-aided design of novel lantibiotics with improved antibiotic properties from August 1, 2021 to July 31, 2022. Specifically, the awardee will investigate the molecular interaction between the lantibiotic mutacin 1140 and its target in silico to rank analogs, synthesize and...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $474,363.00 to Rowan University to develop novel antimicrobial peptides inspired by the clinically approved compound daptomycin. The goal is to create new peptide molecules that mimic daptomycin's key mechanisms of action, such as calcium binding and lipid membrane disruption, while improving resistance to...

This Project Grant, awarded on January 1, 2026, by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $151,040 in funding to Tufts University School of Medicine to conduct fundamental research on bacterial cell division mechanisms in Clostridioides difficile. The research will identify and characterize the unique divisome—the multiprotein complex responsible for bacterial cell division—in this major...

Federal Project Grant Award Summary Microbiotix, Inc. received a Project Grant award of $299,946 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective September 22, 2025, with completion targeted for August 31, 2027. The award supports the development of novel benzyl-piperidine (BP) antifungal agents to treat intractable mucormycosis infections caused by Mucorales fungi, a WHO high-priority...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to develop small molecule inhibitors of the LpxH enzyme as novel antibiotics to treat multidrug-resistant Enterobacterales infections. The $747,763 award to Duke University will fund the design, synthesis, and optimization of potent LpxH inhibitors with desirable drug-like properties. The project aims to establish the...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $299,995 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Xiretsa Inc., a minority-owned small business located in Santa Barbara, CA. The grant will fund the development of a novel class of antimicrobial compounds called Anti-Infective Conjugated Electrolytes (ACEs) that target the bacterial cell membrane to address the growing threat of antimicrobial resistance. The project...

This $298,045 Project Grant award from the National Institutes of Health's National Center for Advancing Translational Sciences (CFDA 93.350) aims to establish and develop a high-throughput screening (HTS) assay to identify novel bacterial DNA gyrase poisoning inhibitors. The key products and services to be delivered under this one-year award include: Developing a unique HTS assay to rapidly discover bacterial DNA gyrase poisoning inhibitors from small molecule libraries. This assay will...